Search - tctmd.com

Displaying 1 - 20 of 102

Sort: Relevancy | Date

Presentation TCT 2024

What’s Next in Acute and Chronic Phase Antithrombotic Therapy in ACS

Presenter: C. Michael Gibson

October 28, 2024

News Conference News ACC 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Yael L. Maxwell

April 06, 2024

Presentation ACC 2024

ApoA-I Event ReducinG in Ischemic Syndromes II (AEGIS-II) Trial

Presenter: C. Michael Gibson

April 06, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2024

Shelley Wood

April 03, 2024

News Daily News

AEGIS-II Misses Primary Endpoint, Dealing New Blow to HDL Hypothesis

Todd Neale

February 14, 2024

News Conference News AHA 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

L.A. McKeown

November 11, 2023

Presentation TCT 2022

New and Emerging Pharmacology for ACS: Factor XI Inhibition

Presenter: C. Michael Gibson

September 19, 2022

Presentation TCT 2022

Novel Approaches to Reduce and Reverse Bleeding in Complex PCI

Presenter: C. Michael Gibson

September 19, 2022

Presentation TCT 2021

Post-PCI Phase (Patient in AFib): Long-term Prevention of Bleeding

Presenter: C. Michael Gibson

November 06, 2021

News Features

Tragedy as Catalyst: How COVID-19 May Transform Clinical Research for Good

Todd Neale

December 14, 2020

News Daily News

Anthony Gershlick, Esteemed UK Cardiologist, Dies at 69

L.A. McKeown

November 20, 2020

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

Caitlin E. Cox

September 03, 2020

Presentation TCT 2019

Case 3: A Patient With AF and ACS

Presenter: C. Michael Gibson

September 28, 2019

Presentation TCT 2019

Approaches to Reduce Bleeding Risk Post PCI in Patients Requiring OAC: Is There Any Role for ASA?

Presenter: C. Michael Gibson

September 28, 2019

Presentation TCT 2019

Reducing Aspirin Use in ACS and PCI (With and Without AFib): How Good Is the Evidence?

Presenter: C. Michael Gibson

September 28, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presentation TCT 2019

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presenter: C. Michael Gibson

September 27, 2019

Presentation TCT 2019

Answers and Questions After AUGUSTUS

Presenter: C. Michael Gibson

September 27, 2019

Presentation TCT 2019

Take Home for Clinicians

Presenter: C. Michael Gibson

September 26, 2019

Presentation TCT 2019

Don’t Forget About Your HDL: The AEGIS Program

Presenter: C. Michael Gibson

September 26, 2019

News Industry News

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

September 25, 2019

Advertisement

What’s Next in Acute and Chronic Phase Antithrombotic Therapy in ACS

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

ApoA-I Event ReducinG in Ischemic Syndromes II (AEGIS-II) Trial

TCTMD’s Top 10 Most Popular Stories for March 2024

AEGIS-II Misses Primary Endpoint, Dealing New Blow to HDL Hypothesis

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

New and Emerging Pharmacology for ACS: Factor XI Inhibition

Novel Approaches to Reduce and Reverse Bleeding in Complex PCI

Post-PCI Phase (Patient in AFib): Long-term Prevention of Bleeding

Tragedy as Catalyst: How COVID-19 May Transform Clinical Research for Good

Anthony Gershlick, Esteemed UK Cardiologist, Dies at 69

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

Case 3: A Patient With AF and ACS

Approaches to Reduce Bleeding Risk Post PCI in Patients Requiring OAC: Is There Any Role for ASA?

Reducing Aspirin Use in ACS and PCI (With and Without AFib): How Good Is the Evidence?

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Answers and Questions After AUGUSTUS

Take Home for Clinicians

Don’t Forget About Your HDL: The AEGIS Program

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content